Impel NeuroPharma
720 Broadway Ave.
Suite 413
Seattle
Washington
United States
Tel: 206-568-1466
Website: http://www.impelneuropharma.com/
41 articles with Impel NeuroPharma
-
Impel Neuropharma Announces FDA Submission Of New Drug Application For INP104 For The Acute Treatment Of Migraine
11/9/2020
Dihydroergotamine mesylate (DHE) is Administered via Impel's Proprietary Precision Olfactory Delivery (POD®) Technology, the First and Only Delivery System to Utilize the Vascular-Rich Upper Nasal Space as a Potential Treatment Pathway
-
Impel NeuroPharma Presents Data From Pivotal Phase 3 Registration Study Of INP104 For The Treatment Of Acute Migraine At 2020 Migraine Trust Virtual Symposium
10/8/2020
66.3% of Patients Reported Pain Relief Within Two Hours of Treatment with Rapid Uptake via the Upper Nasal Space Resulting in Onset of Relief as Early as 15 Minutes for Some Patients Data Suggest Use of Impel's Proprietary Precision Olfactory Delivery (POD®) Technology with DHE May Offer Convenience, Clinical Benefit for Acute Migraine Patients
-
Clinical Catch-Up: June 29-July 3
7/6/2020
Heading into the 4th of July holiday in the U.S., there was still a fair amount of clinical trial news last week. Here’s a look. -
Impel NeuroPharma Announces Publication of Positive Results of SNAP 101 Study for INP105 for the Treatment of Acute Agitation in The Journal of Clinical Psychiatry
6/30/2020
Study Shows INP105 Achieves Rapid Absorption Which May Provide An Effective, Convenient, & Noninvasive Future Alternative for Treating Acute Agitation In the Home, Community, or Hospital Setting
-
Impel NeuroPharma Presents Data From INP104 Clinical Program In Acute Migraine At The 2020 American Headache Society (AHS) Virtual Annual Scientific Meeting
6/15/2020
Four Scientific Poster Presentations Support the Potential of INP104 to Fulfill Key Unmet Needs and If Approved, Become a Transformative New Therapeutic Option for Acute Migraine Additional Data from STOP 301, the Company's Pivotal Phase 3 Study of INP104 for Acute Migraine, Found Majority of Patients Reported INP104 Easy to Use and Preferred Over Current Acute Therapy Impel NeuroPharma Plans to Submit a New Drug Application (NDA) in the Second Half of 2020
-
Clinical Catch-Up: June 8-12
6/15/2020
It was a fairly busy week with clinical trial updates and announcements. Here’s a look. -
Impel NeuroPharma Announces Primary Objectives Met In Pivotal Phase 3 Registration Study Of INP104 For The Treatment Of Acute Migraine
6/10/2020
Exploratory Efficacy Data Reveal INP104 Resulted in Pain Relief in 66.3% of Patients and Pain Freedom in 38% of Patients at Two Hours After First Dose; Additionally, 16.3% of Patients Reported They Gained Initial Relief as Early as 15 Minutes At Weeks 21-24, Over 98% and 95% of Patients Who Experienced Pain Freedom at Two Hours Self-Reported No Recurrence of Migraine Symptoms or Use of Rescue Medications During the 24 and 48-Hour Periods, Respectively, After Using INP104 74%
-
Impel NeuroPharma Announces Leadership Transition, Chairman Adrian Adams' Role Expanded To Chairman And CEO
5/5/2020
Impel NeuroPharma, a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies for patients living with central nervous system (CNS) disorders with high unmet medical needs, today announced an expanded role of Adrian Adams , who served as Chairman of the Board of Directors since
-
BioSpace takes a look at some of the investigational products that could, one day, provide relief for migraine sufferers.
-
Impel NeuroPharma Announces Appointment of Sheena K. Aurora, MD, As Vice President of Medical Affairs - Migraine Franchise
1/16/2020
Impel NeuroPharma, a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies for patients living with central nervous system (CNS) disorders with high unmet medical needs, today announced the appointment of Sheena K. Aurora, MD, as Vice President of Medical Affairs – Migraine Franchise.
-
Impel NeuroPharma Announces Appointment Of Adrian Adams As Chairman Of The Board Of Directors
1/9/2020
Impel NeuroPharma announced the appointment of Adrian Adams as Chairman of the Board, effective January 8, 2020.
-
Impel NeuroPharma Announces Appointment Of Diane Wilfong To Board Of Directors
10/17/2019
Impel NeuroPharma, a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies for patients living with central nervous system (CNS) disorders with high unmet medical needs, today announced that Diane Wilfong has been appointed to the Company's board of directors.
-
Impel NeuroPharma to Present Data From INP104 Clinical Program at the 19th Congress of the International Headache Society
9/5/2019
Impel NeuroPharma, a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies for patients living with central nervous system (CNS) disorders with high unmet medical needs, today announced that it will present four scientific abstracts at the 19th Congress of the International Headache Society (IHC) being held September 5 – 8, 2019 in Dublin, Ireland.
-
Impel NeuroPharma Announces Last Patient Enrolled In Phase 3 Trial Evaluating INP104 For The Treatment Of Acute Migraine
9/3/2019
Impel NeuroPharma, a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies for patients living with central nervous system (CNS) disorders with high unmet medical needs, today announced the last patient has been enrolled in "STOP-301" (Safety and Tolerability of POD-DHE), the Company's pivotal open-label Phase 3, multi-use, long-term safety and tolerability of INP104 for the treatment of acute migraine.
-
Impel NeuroPharma to Present Data From INP104 Clinical Program at the 61st Annual Scientific Meeting of the American Headache Society
7/10/2019
Impel NeuroPharma, a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies for patients living with central nervous system (CNS) disorders with high unmet medical needs, today announcedthat it will present four scientific abstracts at the 61st Annual Scientific Meeting of the American Headache Society (AHS) held July 11-14 in Philadelphia, PA.
-
Impel NeuroPharma Appoints John Leaman as Chief Financial Officer
6/26/2019
Impel NeuroPharma announced the appointment of John Leaman, M.D., as the Company's Chief Financial Officer.
-
Impel Neuropharma to Present Data at 2019 American Psychiatric Association (APA) Annual Meeting
5/17/2019
Impel NeuroPharma, a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies that unlock the full potential of proven medicines for patients living with central nervous system (CNS) disorders with high unmet medical needs, today announced a poster presentation at the upcoming American Psychiatric Association (APA) Annual Meeting,
-
Impel NeuroPharma To Present Data Highlighting Late-Stage Central Nervous System Pipeline At 2019 American Academy Of Neurology Meeting
4/30/2019
Safety, Tolerability and Comparative Bioavailability Data Support INP104, Impel's Nasal Drug Candidate for Acute Migraine
-
April 11 is World Parkinson’s Day, designed to raise awareness of Parkinson’s disease. Parkinson’s is a progressive disease of the nervous system that affects movement.
-
A recent report by the U.S. Bureau of Labor Statistics and CBRE Research identified Seattle—which happens to be the BioSpace Bio Forest Hotbed—as the fastest-growing life science market in the top 10 from 2014 to 2017, with a greater than 17-percent growth.